Emma R. Russell, MSc; Daniel F. Mackay, PhD; Katy Stewart, PhD; et al.
open access
JAMA Neurol. 2021;78(9):1057-1063. doi:10.1001/jamaneurol.2021.2403
This cohort study investigates the association of field position, professional career length, and playing era with risk of neurodegenerative disease among Scottish male former professional soccer players.
Gregory W. Albers, MD; Maarten G. Lansberg, MD, PhD; Scott Brown, PhD; et al.
free access
JAMA Neurol. 2021;78(9):1064-1071. doi:10.1001/jamaneurol.2021.2319
This pooled analysis uses data from 6 randomized clinical trials to assess the potential benefits of endovascular thrombectomy among patients with ischemic stroke based on 3 baseline imaging profiles.
Osvaldo P. Almeida, PhD; Graeme J. Hankey, MD; Andrew Ford, PhD; et al.
free access
JAMA Neurol. 2021;78(9):1072-1079. doi:10.1001/jamaneurol.2021.2418
This randomized clinical trial investigates whether daily treatment with 20 mg of fluoxetine hydrochloride reduces the proportion of people affected by symptoms of depression after stroke.
Stevie Hendriks, MSc; Kirsten Peetoom, PhD; Christian Bakker, PhD; et al.
free access
JAMA Neurol. 2021;78(9):1080-1090. doi:10.1001/jamaneurol.2021.2161
This systematic review and meta-analysis assesses the global prevalence of young-onset dementia.
Yongjun Wang, MD; Yuesong Pan, PhD; Hao Li, PhD; et al.
open access
JAMA Neurol. 2021;78(9):1091-1098. doi:10.1001/jamaneurol.2021.2440
This exploratory analysis of the THALES trial evaluates the efficacy and safety of ticagrelor plus aspirin in patients with moderate ischemic stroke (National Institutes of Health Stroke Scale score of 4 to 5).
Manuel Requena, PhD; Marta Olivé-Gadea, MD; Marian Muchada, PhD; et al.
free access
JAMA Neurol. 2021;78(9):1099-1107. doi:10.1001/jamaneurol.2021.2385
This randomized clinical trial assesses whether direct transfer to the angiography suite improves clinical outcomes compared with usual imaging workflow among patients within 6 hours from onset of symptoms for large vessel occlusion ischemic stroke.
Michelle M. Mielke, PhD; Ryan D. Frank, MS; Jeffrey L. Dage, PhD; et al.
free access
JAMA Neurol. 2021;78(9):1108-1117. doi:10.1001/jamaneurol.2021.2293
This cross-sectional study compares amyloid and tau positron emission tomography measures, neurodegeneration, vascular pathology, and cognitive outcomes using plasma p-tau181 and p-tau231 on the single-molecule array platform vs p-tau181 and p-tau217 on the Meso Scale Discovery platform among participants without dementia enrolled in the Mayo Clinic Study on Aging.
Pavel Klein, MBBChir; Orrin Devinsky, MD; Jacqueline French, MD; et al.
free access
JAMA Neurol. 2021;78(9):1118-1127. doi:10.1001/jamaneurol.2021.2480
This meta-analysis reviews placebo-controlled phase 2 and 3 studies of 10 antiseizure medications approved since 2008 to evaluate the risk of suicidality of these drugs compared with placebo.
Felipe J. S. Jones, MD; Paula R. Sanches, MD; Jason R. Smith, BA; et al.
free access
has audio
JAMA Neurol. 2021;78(9):1128-1136. doi:10.1001/jamaneurol.2021.2249
This decision analytic study uses a simulation model to evaluate the trade-offs associated with 4 treatment strategies based on primary vs secondary prophylactic therapy, timing of seizures, and duration of therapy in patients with spontaneous intracerebral hemorrhage.
-
Podcast:
Seizure Prophylaxis After Spontaneous Intracerebral Hemorrhage
Esther L. Yuh, MD, PhD; Sonia Jain, PhD; Xiaoying Sun, MS; et al.
open access
JAMA Neurol. 2021;78(9):1137-1148. doi:10.1001/jamaneurol.2021.2120
The longitudinal, observational study aims to identify pathological computed tomography features associated with adverse outcomes after mild traumatic brain injury.